{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal PrimePro",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                              "13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                              "7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                              "7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PrimePro",
                              "Other: Placebo",
                              "Biological: PrimePro",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVID-19 Patients Experimental",
                              "COVID-19 Patients Placebo",
                              "Healthcare Providers Experimental",
                              "Healthcare Providers Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04573270"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiovascular disorders and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for diabetes complications. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for integumentary diseases and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic and musculoskeletal conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic and neurodegenerative disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for sexual dysfunction conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for viral illnesses. Outcomes will be compared to results in peer-reviewed literature for several conditions."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1: Autoimmune Diseases",
                              "Arm 2: Cardiovascular Disorders",
                              "Arm 3: Diabetes Complications",
                              "Arm 4: Integumentary Disease",
                              "Arm 5: Musculoskeletal Disorders",
                              "Arm 6: Neurodegenerative Disorders",
                              "Arm 7: Pulmonary Disorders",
                              "Arm 8: Sexual Dysfunction",
                              "Arm 9: Urologic Disorders",
                              "Arm 10: Viral Illnesses"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04684602"
                        ]
                  }
            ]
      }
}